Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325792 · ClinicalTrials.gov registry record
Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement
A clinical trial, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- 104
- Enrollment target
NCT01325792: Completed study, sponsored by W.L.Gore & Associates.
NCT01325792 is a clinical trial that has completed, run by W.L.Gore & Associates. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01325792 has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- 104 participants
- Enrollment target
Study Summary
Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.
Primary Outcome
Investigator confirmed hernia recurrence by physical examination
Interventions
- DEVICE GORE® BIO-A® Tissue Reinforcement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-12 |
What the finished NCT01325792 record still lists
NCT01325792 is an observational study that tracks outcomes without assigning an intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which GORE® BIO-A® Tissue Reinforcement is the first listed.
NCT01325792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01325792 about?
NCT01325792 is a clinical study titled "Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement". Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.
What is the current status of trial NCT01325792?
This trial is currently completed. The enrollment target is 104 participants. The study started on 2011-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01325792?
The interventions under investigation include: GORE® BIO-A® Tissue Reinforcement (DEVICE).
Who is sponsoring clinical trial NCT01325792?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia